US-based clinical-stage specialist pharmaceutical firm EyeGate Pharmaceuticals has reported positive topline results from the first-in-human pilot trial of its EyeGate Ocular Bandage Gel (EyeGate OBG) in corneal epithelial defects.

The EyeGate OBG is a clear viscous hydrogel eye drop with a 0.75% concentration of CMHA-S hydrogel developed to bolster the re-epithelialisation of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The gel is claimed to be capable of coating the ocular surface with little to no optical blur and resists degradation under conditions of the eye.

The prospective, randomised, controlled study conducted in 39 subjects undergoing bilateral PRK surgery evaluated the safety and efficacy of EyeGate OBG as a monotherapy or in combination with a Bandage Contact Lens (BCL).

The primary endpoint of the study was complete wound closure by the third day.

See Also:

"The positive results from this pilot study of Eyegate OBG reinforces our belief in the product’s potential as a viable option for the treatment of corneal epithelial defects."

EyeGate chief medical officer Barbara Wirostko said: “Corneal epithelial defects represent a large, underserved market with no approved eye drops available in the United States for accelerating corneal re-epithelisation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Such defects can lead to occular infections, inflammation, corneal neovascularisation, and vision loss if not treated promptly and effectively.

"The positive results from this pilot study of Eyegate OBG reinforces our belief in the product’s potential as a viable option for the treatment of corneal epithelial defects.”

The results indicated the safety and tolerability of EyeGate OBG and was found to meet the primary endpoint.

In the second quarter of this year, the firm intends to conduct a double-blind, controlled trial based on these results to assess EyeGate OBG monotherapy against BCL.